Fennell George, SVP and Chief Revenue Officer, has demonstrated a clear selling bias in their trading activity involving IDXX (IDEXX Laboratories), with $16.9 million in total sales compared to $2.4 million in purchases across 45 transactions. The recent activity, concentrated in February 2026, shows eight sales totaling over $6.8 million, including a single-day disposition of $1.82 million on February 10. That date alone accounted for multiple high-value sales, with transactions ranging from $255,674 to $1.8 million. The pattern suggests a consistent reduction in holdings, as no buys have been recorded in recent filings. Smaller sales, such as a $26,013 transaction also on February 10, appear alongside larger dispositions, indicating a broad unwinding of positions rather than isolated adjustments.
Historical filings reveal a similar trend, with a $59,122 sale on February 14, 2025, though the bulk of George’s activity has occurred in 2026. The absence of any recent acquisitions—coupled with the magnitude of sales—points to a deliberate shift away from IDXX equity. While some transactions, such as those coded "M" (merger or acquisition-related) or "A" (grant/award), show no monetary value, the "S"-coded sales dominate the record. The consistency of these disposals, particularly their clustering in early February, suggests a structured divestment approach rather than sporadic trading. All activity remains confined to IDXX, with no diversification into other securities.
AI-assisted summary